Equities

Chiasma Inc

Chiasma Inc

Actions
  • Price (USD)4.20
  • Today's Change-0.01 / -0.24%
  • Shares traded701.19k
  • 1 Year change-40.34%
  • Beta1.2492
Data delayed at least 15 minutes, as of Jun 21 2021 21:00 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Chiasma, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone. Octreotide is an analog of somatostatin, a natural inhibitor of growth hormone secretion. The Company is developing octreotide capsules as a liquid-filled solid gelatin capsule formulation, which is intended to be taken over twice a day. The Company's TPE technology enhances the absorption through the intestinal wall of drugs. The Company also focuses on developing CH2 for Orphan indication.

  • Revenue in USD (TTM)3.03m
  • Net income in USD-89.94m
  • Incorporated2001
  • Employees85.00
  • Location
    Chiasma Inc140 Kendrick Street, Building C EastNEEDHAM 02494United StatesUSA
  • Phone+1 (617) 928-5300
  • Fax+1 (339) 200-3009
  • Websitehttp://www.chiasmapharma.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Ainos Inc3.48k-1.61m227.58m2.00------65,397.97-0.039-0.0390.00008-0.03040.00990.8452--1,740.00-458.23-113.03----50.5759.31-46,200.00-1,585.120.0282-75.23----41.18--8.26---8.97--
AVEO Pharmaceuticals, Inc.7.16m-49.33m231.59m49.00--3.20--32.37-1.99-1.990.29542.110.0862--3.65146,020.40-59.43-58.85-79.45-108.8824.91---689.38-245.32---23.100.3093---79.10-20.56-479.04--75.18--
Unity Biotechnology Inc0.00-81.56m233.13m63.00--2.91-----1.56-1.560.001.460.00----0.00-53.31---58.02-------------59.650.236-------14.20------
Jaguar Health Inc9.76m-42.24m233.44m34.00--6.93--23.93-0.8961-0.89610.14750.24530.19131.152.80286,970.60-74.29-92.73-103.60-172.0367.3455.17-388.25-586.393.28-2.900.4459--62.50105.1313.59---21.38--
Spruce Biosciences Inc-100.00bn-100.00bn236.10m19.00--1.68----------6.04----------------------------0.0333-------125.70------
Adamas Pharmaceuticals Inc79.29m-53.33m236.12m138.00--39.77--2.98-1.79-1.792.640.13080.50580.28668.73574,572.40-34.01-52.13-40.93-59.1697.67---67.26-269.735.16-3.180.9562--36.28107.9345.43------
Chiasma Inc3.03m-89.94m243.16m85.00--3.88--80.25-1.60-1.600.05281.080.0246----35,647.06-73.05-46.47-83.46-53.7495.78---2,968.35-20,732.107.08-8.350.00-------105.89--6.70--
Tricida Inc0.00-244.04m243.32m64.00--3.95-----4.87-4.870.001.220.00----0.00-87.88---105.41-------------10.010.6624-------49.76------
Sanara Medtech Inc17.07m-3.70m243.71m40.00--6.77--14.28-0.5819-0.58192.734.720.70341.619.08426,802.00-15.60-32.98-17.36-51.4689.6988.71-22.19-17.709.69-41.950.00--32.4735.82-54.81--214.67--
Alseres Pharmaceuticals, Inc.473.72k-776.63k245.09m3.00------517.36-126.75-126.7577.28-1,790.952.22-------363.83-523.93---------163.94-1,566.44---3.09-----10.74--42.78------
Galera Therapeutics Inc0.00-74.52m245.22m38.00---------2.99-2.990.00-0.41970.00----0.00-74.04---86.25-------------16.271.20-------25.57------
Chemomab Therapeutics Ltd - ADR0.00-9.78m246.69m3.00--0.2718-----73.12-73.120.0082.500.00----0.00-25.97---29.10--------------0.00------57.20------
Corbus Pharmaceuticals Holdings Inc2.82m-97.68m247.57m76.00--2.71--87.70-1.18-1.180.03140.73190.0275--0.841537,144.61-95.13-121.89-132.81-192.93-----3,460.08-590.43---41.910.169---89.1143.44-55.72--33.55--
Atreca Inc0.00-91.69m249.88m134.00--1.38-----2.70-2.700.006.000.00----0.00-41.61---44.17--------------0.0002-------27.93------
Kezar Life Sciences Inc0.00-44.72m256.80m47.00--1.83-----0.9198-0.91980.002.930.00----0.00-31.17---32.81--------------0.00-------18.97------
Data as of Jun 21 2021. Currency figures normalised to Chiasma Inc's reporting currency: US Dollar USD

Institutional shareholders

52.86%Per cent of shares held by top holders
HolderShares% Held
Rubric Capital Management LPas of 31 May 20217.25m12.52%
Stonepine Capital Management LLCas of 06 May 20216.77m11.69%
BlackRock Fund Advisorsas of 31 Mar 20214.00m6.91%
Eventide Asset Management LLCas of 31 Mar 20213.00m5.18%
The Vanguard Group, Inc.as of 31 Mar 20212.76m4.77%
Rock Springs Capital Management LPas of 31 Mar 20212.17m3.76%
Adage Capital Management LPas of 31 Mar 20211.50m2.59%
Jacobs Levy Equity Management, Inc.as of 31 Mar 20211.16m2.01%
Bruce & Co., Inc.as of 31 Mar 20211.15m1.99%
Geode Capital Management LLCas of 31 Mar 2021836.14k1.44%
More ▼
Data from 31 Mar 2021 - 31 Mar 2021Source: FactSet Research Systems Inc.
Refinitiv, an LSEG business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.